ASND Stock Analysis: Buy, Sell, or Hold?
ASND - Ascendis Pharma A/S American Depositary Shares
$253.29
-1.52 (-0.60%)
âŧ
5d:
+1.93%
30d:
+0.25%
90d:
+2.34%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When ASND Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ASND is fairly priced but lacks strong directional signals. At 0.7% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ASND is fairly priced but lacks strong directional signals. At 0.7% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$103.22
Based on -12.0% avg growth
INTRINSIC VALUE TODAY
$64.09
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ASND is currently trading at $253.29, which is considered fair relative to its 30-day fair value range of $247.01 to $258.99. The stock's valuation (Forward PE: 31.1) is in line with its historical norms (30.4). At these levels, the market is pricing in 0.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ASND is in a uptrend. Immediate support is located at $240.64, while resistance sits at $261.61.
Market Sentiment: ASND scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $313.69 (+23.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ASND is in a uptrend. Immediate support is located at $240.64, while resistance sits at $261.61.
Market Sentiment: ASND scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $313.69 (+23.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$247.01 -
$258.99
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (65/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 23.8% below Wall St target ($313.69)
- NEUTRAL: Market pricing in 0.7% annual earnings growth - fairly valued
- WARNING: Composite score 51/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$247.01 -
$258.99
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$240.64
Resistance Level
$261.61
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
31.05
Wall Street Target
$313.69
(+23.8%)
Revenue Growth (YoY)
114.7%
Profit Margin
70.9%
Valuation Premium vs History
+0.7% premium
PE vs Historical
31.1 vs 30.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.7%
(market-implied from PE analysis)
1-Year Target
$255.06
(+1%)
2-Year Target
$256.85
(+1%)
3-Year Target
$258.65
(+2%)
3-Yr Target (if PE normalizes)
(PE: 31â30)
PE COMPRESSION
$253.27
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 31.0, Growth: -28.0%)
$184.65
(+-27%)
Base:
(SPY PE: 20.1, Growth: -28.0%)
$119.37
(-53%)
Bear:
(PE: 17.1, Growth: -28.0%)
$101.47
(-60%)
đ
Valuation based on Current Earnings
Trailing PE: 19.69 | Current EPS (TTM): $12.94
Bull Case
$176.73
(-30%)
Analyst growth -36.9%, PE expands to 21.7
Base Case
$160.66
(-37%)
Market implied -36.9%, PE stable at 19.7
Bear Case
$173.27
(-32%)
Severe decline -20.0%, PE contracts to 16.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 22, 2026 12:40 PM ET
Data refreshes hourly during market hours. Next update: 1:40 PM
Data refreshes hourly during market hours. Next update: 1:40 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ASND showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 33 SELL |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$834 | 34 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 55 HOLD |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$39 | 52 HOLD |
